The U.S. News and World Report rankings are a clear indicator that the SynCardia Total Artificial Heart is rapidly becoming the new standard of care for end-stage biventricular heart failure.
Tucson, AZ (PRWEB) July 19, 2012
SynCardia Systems, Inc., manufacturer of the world’s first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that among the top 50 centers honored in U.S. News & World Report’s “Best Hospitals” list for cardiology and heart surgery, 15 are certified to implant the SynCardia temporary Total Artificial Heart, five are currently completing certification and an additional five are starting certification.
“The U.S. News and World Report rankings are a clear indicator that the SynCardia Total Artificial Heart is rapidly becoming the new standard of care for end-stage biventricular heart failure,” said Michael Garippa, SynCardia Chairman/CEO/President.
During Q1 2012, SynCardia Certified Centers set a new record for Total Artificial Heart implants performed in a single quarter. Through the first half of 2012, implants have increased by 48% compared to the same period last year. There are currently 34 SynCardia Certified Centers in U.S. and 67 worldwide.
In June, U.S. News and World Report published a list of the “Best Children’s Hospitals” for cardiology and heart surgery. Among the top 10 were three pediatric centers that offer the SynCardia Total Artificial Heart: The Children's Hospital of Philadelphia (CHOP) ranked #2, Texas Children's Hospital ranked #3 and Cincinnati Children's Hospital Medical Center ranked #9. Several additional top pediatric centers are planning to add the Total Artificial Heart to their programs by the end of the year.
Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for patients suffering from end-stage heart failure affecting both sides of the heart (biventricular failure). There have been more than 1,000 implants of the Total Artificial Heart, accounting for more than 270 patient years of life.
About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, SynCardia's Total Artificial Heart is currently approved as a bridge to transplant for people dying from end-stage biventricular heart failure. There have been more than 1,000 implants of the Total Artificial Heart, accounting for more than 270 patient years of life.
Similar to a heart transplant, SynCardia's Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers and does not require expensive anti-rejection medication, which can cause subsequent complications. It is the only device that provides immediate, safe blood flow of up to 9.5 liters per minute through both ventricles. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.
SynCardia Ranked #20 Among World's 50 Most Innovative Companies
In March 2011, Fast Company magazine ranked SynCardia #20 in its annual list of the "World's 50 Most Innovative Companies" for "giving mobility to artificial heart recipients." Weighing 13.5 pounds, SynCardia's Freedom® portable driver is the world's first wearable driver designed to power the Total Artificial Heart both inside and outside the hospital. The Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.